{
  "docId": "019de074-6c10-759a-a503-c8b869115e9a",
  "docSlug": "3f9321c37d26dde2e5a75b53f195ef9c",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 31 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 31,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 24,
  "notes": "Includes a detailed table for Trelegy Ellipta royalties and milestones by year.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-6c10-759a-a503-c8b869115e9a/30",
  "deckHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a",
  "deckJsonHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json",
  "deckAnchorHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.53,
        "y": 0.32
      },
      "kind": "list",
      "text": "Upfront payment: $25M (Received)\n1st Regulatory approval milestone: $15M\nFuture royalties paid to Royalty Pharma: 2.5% on annual global net sales up to $500M; 4.5% on annual global net sales > $500M",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24db60ca-24c0-4682-a083-9fb031536b20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "list",
      "text": "Upfront: $1.1B (Received)\nMilestones: Up to $250M",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b02a397d-b5b7-46c7-b367-07b6ec28f582",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.6,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "Ampreloxetine (Unsecured Royalty)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13873da4-9c9f-429c-a404-bbfae1db8608",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.15,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "TRELEGY ELLIPTA",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25cdd43f-40ca-4338-b2b3-220fb6913730",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.06,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Outer Year Royalty (\"OYR\"): 85% of royalties for TRELEGY ELLIPTA return to Theravance Biopharma: On and after January 1, 2031 for U.S. sales; On and after July 1, 2029 for ex-U.S. sales",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46888430-b700-49bc-9826-0015fcf0cfcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. If both milestones are achieved in a given year, Theravance Biopharma will only earn the higher milestone. 2. Based on 100% of TRELEGY ELLIPTA royalties. 3. U.S. royalties expected to end late 2032; ex-U.S. royalties expected to end mid-2030s.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6535291-ade5-40c9-be6d-9bea7e6fc77b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.11,
        "y": 0.38
      },
      "kind": "table",
      "text": "Year, Royalties, Global Net Sales Equivalent, Milestone table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c032ca5a-b5ab-4472-80a1-f9816c71d97c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Theravance Biopharma and Royalty Pharma Deal Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10968461-c9bc-4358-823e-ab6923b03090",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}